Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doog- The new NDAs are bait to call in the sheep. He don't even care about the NASDAQ listing anymore. He is just trying to get his grimy hands on another $5-10M so he can still be the big boss man at this pathetic company for another 6 months. I hope the new shareholders look at what he promised for 2018 and what he has actually done... Same as always... Pretty much no progress on anything relevant.
12-24 months to get international markets going is ridiculous... I mean they have had these approvals for a long time... Did they just realize they could sell them in other countries and it will take 12 months to get this going? 12 months sounds like Odidi is trying to buy time with his new heard of sheep that he is calling in When I spoke with Patient earlier this year he told me about the international markets. He said they were low volume markets that would accept FDA approvals. He said they were doing packaging tests as we speak and he though they may be selling later in 2018. I mean what the F*** do these guys do all day? They have a VP of Commercial Operations and they haven't made a deal in years... This company is a playground for the Odidi's.
At current price, it appears Odidi will sell more than half the company to get about $6-7M... All I can say is WOW! I mean how desperate is this guys to get his grimy hands on another couple million? He had other options like selling off ANDAs, etc. Reducing staff at IPCI. But no, he is always right and will continue business as usual selling more than half the company to get him another 6 months tops...
Was the PODRAS data on Page 20 of presentation actual human testing? It was listed as pre-clinical test results. Is this the data they were supposed to be collecting 1H of this year in the 1st human trials or is this just more of the same that they have shown in the past?
MS Oral medications
Aubagio (teriflunomide)
Gilenya (fingolimod)
Tecfidera (dimethyl fumarate)
Fabius- He will keep control because nobody actually wants control of IPCI. The company is a joke. The technology is not as good as he says. The FDA applications were second rate. Nobody in their right mind wants to run this piece of garbage. The offering/warrants will be bought by the same groups that always buy. They will make their money any way they can. Up, down, sideways, etc. They will off load the shares on the sheep immediately with a pump. and just hold enough for shorting and of course the warrants. They do not want anything to do with IPCI. The just want to trade it, etc.
Now will Boyd do something? Maybe? Are the latest confidential NDAs possibly alligned with Boyd/Cerecor? I have not had time to research but that would be the only hope for three new NDAs... That Boyd is behind them. If not, just bait for retail sheep to buy offering from Wainwright/Sabby/Anson, etc.
Odidi and Patient have not been returning calls to existing shareholders for some time... Everyone was asking for an update... But nothing until they are trying to sell a ton more shares... Then we hear about three new confidential NDAs. What a scam! They have Regabatin NDA that has not advanced in years... At the start of the year they said hios would be partnered mid year... And still nothing... Now they claim to have three new NDAs that are confidential and not partnered. I hope people that are considering buying this offering are taking this with a grain of salt. These are nothing more than bait to sucker in new shareholders so that Odidi can get his $10M and keep the doors open until March 2019.
Angelo- You are definitely in denial. Even if PODRAS worked in say Tylenol the added cost would pretty much make it a no go. I think you know what happened with PODRAS. They tested it and it was not what they expected. Now they are tweaking/reformulating, etc. The problem is he is out of money and out of time. The offering will give him 6 more months. A very desperate attempt to hold onto a near lost cause. The only thing that can save this company is real good HAP test results and a strong partner. If that doesn't happen, IPCI will be done by mid 2019.
wimike- I hear ya... I have seen this coming for weeks... This is desperate measure by a desperate man to buy 6 more months and then POOF company is gone. For sure Odidi and IPCI are on the verge of several shareholder lawsuits as well.
Impact- So I guess you will cover all the ones you recently short sold with the ones you are getting from the offering. This price drop is fully driven by the pricing of the next offering by Wainwright. By them dropping the price, it is 100% apparent they will price offering very soon.
If you buy a hot dog at Odidi's hot dog stand it will also include a prefunded warrant to buy another!
I guess he will do anything to get his hands on a few more million and keep this pathetic company going. I ma not exactly sure what all the employees do every day. The only real this going on is Rexista.
So are they planning on selling 1 or 2 shares for $2.44?
[/All historical references to Common Shares, warrants and options outstanding prior to September 12, 2018 and the related exercise prices
and conversion prices in this prospectus have been adjusted to reflect the effect of the reverse split. We have assumed a public offering
price of $2.45 per Unit and $2.44 per Pre-Funded Unit. The actual offering price per Unit and Pre-Funded Unit, and the exercise price of the
Warrants, as applicable, will be determined by negotiation between us and the underwriter based on market conditions at the time of
pricing, and may be at a discount to the current market price of our Common Shares. We do not intend to apply for listing of the Pre-
Funded Warrants or the Warrants on any securities exchange or other nationally recognized trading system. There is no established public
trading market for the Pre-Funded Warrants or the Warrants, and we do not expect a market to develop. Without an active trading market,
the liquidity of the Pre-Funded Warrants and the Warrants will be limited.i]
Fabius- Does the following say they are selling 4.8M shares or 9.6M shares?
INTELLIPHARMACEUTICS INTERNATIONAL INC.
Up to 4,897,960 Units (each Unit contains one Common Share and one Warrant to purchase one Common Share)
Up to 4,897,960 Pre-Funded Units (each Pre-Funded Unit contains one Pre-Funded Warrant to purchase one Common Share and
one Warrant to purchase one Common Share)
(4,897,960 Common Shares Underlying the Warrants) and
(4,897,960 Common Shares Underlying the Pre-Funded Warrants)
We are offering up to 4,897,960 Units (“Units”), each Unit consisting of one common share, no par value (“Common Shares”),
and one warrant (the “Warrant”) to purchase one Common Share. Each Warrant contained in a Unit has an exercise price of $ per Common
Share. The Warrants contained in the Units will be exercisable immediately and will expire . We are also offering the Common Shares that
are issuable from time to time upon exercise of the Warrants contained in the Units.
Doog- What I honestly don't understand is how Odidi feels he is doing an adequate job and should continue to be CEO of IPCI. In all reality, he just buys more time through offerings. His pipeline and management has not brought the company to cash flow neutrality. So this offering is just delaying the inevitable. I think he has ulterior motives at this point. I think he holds onto the ANDAs because he wants to buy them on the cheap and then eventually manufacture them in China. I guess he had a great business plan. Get a bunch of suckers to finance his business while he develops some drugs and gets them approved. But then never markets these drugs and lets company fail. He then buys these ANDAs on the cheap and off to China he goes and has Shanghai Yunfeng manufacture them for him. Then Smart Pharma wholesale sells these around the world. Smart Pharma has no overhead or costs and he justs takes a cut in the profits. Great business plan for Odidi and he will collect profits on these drugs for years. And the best thisng for Odidi is he doesn't have to share those profits with shareholders as he IPCI went bankrupt.
Good thing Odidi has that MBA... It has helped him do such a great job at making IPCI the huge success he promised with a market cap of $0.5-1B! HAHAHAHAHA
Weezuhl- Odidi will never convert those loans to shares. First the strike price on the old one is something like $30 per share... Second he never invests any real money in IPCI. He just loans it to them at 10-12% with an option to buy shares...
Fabius- Yes it was E Star Capital. So far what he said months ago was spot on. So I am guessing the next thing we get is:
1. Earnings... Not good...
2. Company update through earnings that pretty much shows no progress at all. Lets hope they actually can show some progress on things they promised early this year.
3. Offering for about 7.5M shares at about $2.
Now if they have good HAP studies and can partner Rexista, things would be different. But I think that is not going to happen by Oct 17th. I know people are optimistic that the 17th is because he is finishing a deal. Well he is... It is the finalization of the offering.
wimike- I hope I am wrong too. But based on Odidi's track record we can't expect much. My take is he only is worried about saving face and employees jobs at IPCI(especially him and his wife). He could care less about shareholders and his shares. I mean how many shares did he ever actually pay for? I have never seen anything that showed he purchased any. I am guessing he got most of them when the company was formed. I hate to say it but I think everyone sees what is coming. They just don't want to admit it yet. He is going to dilute in a major way. That is the plan. That has always been the plan. I think some poster with the name something capital said months ago- prior to RS announcement when everyone was speculating on company filing- that RS was going to be 10-1 and that after dilution we would be at $2 per share(I believe he referenced Patient said this). He has been 100% right so far... So in the end we get the shaft and Odidi will continue on business as usual. Making promises he never keeps and never actually advancing a pipeline that is now virtually worthless.
Fabius- The only thing I see that POS doing is selling $15M at $2 per share. He has failed and failed and failed... And he hasn't done crap this year... Why would this time be different? He is out of touch with reality and is now going to say he just needs a little more money as Rexista will be approved next year... Then when it comes time for Rexista approval he won't be answering or returning calls to shareholders anymore. Just like now.
And who the F*** is going to buy those warrants at $7.50 and $10? The price right now is under $3 and to think we are going to hit $7-10 really soon is idiocy. I hope I am wrong but I think someone just holding price up so Odidi can sell 7.5M shares at $2.
Amigo- I agree with you regarding the shareholder equity. That is why I have been saying they will need to sell a lot of shares to get to that point. Hence the reason for the $15M offering.
Remember all the talk about revenue prior to Seroquel release? I was very optimistic that they would actually make some money there. When Odidi did not deliver on Seroquel, that is when I realized he would likely never deliver on anything.
The big question is if IPCI has something substantial to announce before they dilute.
Tilator- Cash flow neutrality? Are you crazy? They will be lucky to have $1M in revenue... What has changed that would drive revenue that high- on the order of $3M? And by the way, they have been promising cash flow positive status for years...
Fabius- I hope they have news but I suspect just a compnay update and offering. Remember earnings are due out mid October. Yet another reason for shorts to push this down.
molar- Once again Impact shows that when he says buy, he really meant sell...
Doog- Agreed 100%. IPCI was denied due to an incomplete application. No oral and nasal HAP studies. As well as no study whatsoever on the blue dye.
Weezuhl you are funny too... You are the only person I know who would attend an ADCOM for a company you have no vested interest in...
A huge win for ipci is no food effect. I believe no one else can claim this including eltp. I believe they received a crl on their product due to food effect.
And remember he has vested interest in IPCI not being approved as he is invested in a competitor. A competitor who has been a failure in all aspects of business/technology as well.
Samsa- Remember ELTP's technology is non PEO. So he is a believer that the PEO tech is inferior to ELTP's and he goes to large extents to prove this. I will wait for the results. Would not surprise is Odidi did screw up on this as well. But I will wait and see.
Fabius- Don't forget, he lost a ton of money in ELTP. So the last thing I would do is ask him for investment advice
Fabius- So the question is what has everyone at IPCI been doing in 2018? Sure looks to me like not much.
wimike- Remember the big song and dance about what they would do in 2018? As far as I can see the only thing they did thus far was start the HAP studies. And those are third party... Like I have been saying for a long, long time... What do they actually do with the 50 employees at IPCI?
So when is the big announcement and update Impact Trader? You told us big news coming, I am just wondering when.
Tilator- Keeping blue dye in will require a PH3 study. IPCI would still say that the blue dye is a good idea and may be in a product some day. But to skip a PH3 study(that would cost a few million) IPCI chose to remove.
Here is an issue why Xtampza is not that commercially viable- it has to be taken with food...
DOSAGE AND ADMINISTRATION — The recommended starting dosage of Xtampza ER for opioid-naive patients is 9 mg every 12 hours. The capsules must be taken with food; patients should consume the same amount of food with every dose in order to ensure consistent plasma levels. For patients who have difficulty swallowing the capsules, their contents can be sprinkled on soft foods or into a cup, and then given orally or through a gastrostomy or nasogastric tube. The maximum daily dose of Xtampza ER is 288 mg (equivalent to 320 mg oxycodone HCl). The package insert contains dosing instructions for conversion from other oxycodone formulations or other opioids. Patients with hepatic impairment starting Xtampza ER should take one-third to onehalf the usual dosage; they should not take the drug if the required dose is <9 mg. Patients should be monitored for respiratory depression for 72 hours after either starting treatment or increasing the dose.
Weezuhl- Xtampza has a food effect issue... That is why it is not commercially successful. Seems to me like IPCI has already released data that shows Rexista has no food effect. Do not underestimate the importance of no food effect.
Weezuhl- If the HAP results are good, partners will be lined up, if no partner, then we know.